Cargando…

A randomized, double-blind clinical study to determine the effect of ANKASCIN 568 plus on blood glucose regulation

Diabetes is the fourth major cause of death in Taiwan. High blood glucose can lead to macrovascular diseases,small vessel diseases (retinopathy, kidney disease), and neuropathy. This study aimed to investigate whether Monascus-fermented products (ANKASCIN 568 plus) can regulate blood glucose and blo...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yin-Ruei, Liu, Sheng-Fu, Shen, You-Cheng, Chen, Chien-Li, Huang, Chine-Ning, Pan, Tzu-Ming, Wang, Chin-Kun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taiwan Food and Drug Administration 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9332536/
https://www.ncbi.nlm.nih.gov/pubmed/28911684
http://dx.doi.org/10.1016/j.jfda.2016.06.011
_version_ 1784758671932129280
author Wang, Yin-Ruei
Liu, Sheng-Fu
Shen, You-Cheng
Chen, Chien-Li
Huang, Chine-Ning
Pan, Tzu-Ming
Wang, Chin-Kun
author_facet Wang, Yin-Ruei
Liu, Sheng-Fu
Shen, You-Cheng
Chen, Chien-Li
Huang, Chine-Ning
Pan, Tzu-Ming
Wang, Chin-Kun
author_sort Wang, Yin-Ruei
collection PubMed
description Diabetes is the fourth major cause of death in Taiwan. High blood glucose can lead to macrovascular diseases,small vessel diseases (retinopathy, kidney disease), and neuropathy. This study aimed to investigate whether Monascus-fermented products (ANKASCIN 568 plus) can regulate blood glucose and blood lipids. This study enrolled 39 patients with a fasting blood glucose level between 100 mg/dL and 180 mg/dL, and a glycated hemoglobin (HbA1c) level of <9%. All patients were randomly divided into placebo (n = 20) and experimental (n = 19) groups. Each patient received two placebo capsules (maltodextrin) or ANKASCIN 568 plus capsules daily for 12 weeks. The patients were screened during follow-up 4 weeks after the administration of sample or placebo had been discontinued. Blood and urine samples were collected at the initial, 6(th) week, 12(th) week, and 16(th) week. The anthropometric indicators of blood pressure, fasting plasma glucose level, postprandial plasma glucose level, insulin level, insulin resistance, blood lipid changes, and liver, kidney, and thyroid function indices were measured. After 6weeks, changes in fasting blood glucose, low-density lipoprotein cholesterol (LDL-C),and total cholesterol (TC) levels showed thatANKASCIN568 plus had amore favorable effect than the placebo. Compared to baseline, a statistically significant decrease of 8.5%, 10.3%, and 7.5% was observed in fasting blood glucose, LDL-C and, TC levels, respectively (p < 0.05 for all pairs). Therefore, ANKASCIN568 plus produced by Monascus purpureus NTU 568 fermentation may be a potentially useful agent for the regulation of blood glucose and blood lipids and for treatment of coronary artery diseases.
format Online
Article
Text
id pubmed-9332536
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Taiwan Food and Drug Administration
record_format MEDLINE/PubMed
spelling pubmed-93325362022-08-09 A randomized, double-blind clinical study to determine the effect of ANKASCIN 568 plus on blood glucose regulation Wang, Yin-Ruei Liu, Sheng-Fu Shen, You-Cheng Chen, Chien-Li Huang, Chine-Ning Pan, Tzu-Ming Wang, Chin-Kun J Food Drug Anal Original Article Diabetes is the fourth major cause of death in Taiwan. High blood glucose can lead to macrovascular diseases,small vessel diseases (retinopathy, kidney disease), and neuropathy. This study aimed to investigate whether Monascus-fermented products (ANKASCIN 568 plus) can regulate blood glucose and blood lipids. This study enrolled 39 patients with a fasting blood glucose level between 100 mg/dL and 180 mg/dL, and a glycated hemoglobin (HbA1c) level of <9%. All patients were randomly divided into placebo (n = 20) and experimental (n = 19) groups. Each patient received two placebo capsules (maltodextrin) or ANKASCIN 568 plus capsules daily for 12 weeks. The patients were screened during follow-up 4 weeks after the administration of sample or placebo had been discontinued. Blood and urine samples were collected at the initial, 6(th) week, 12(th) week, and 16(th) week. The anthropometric indicators of blood pressure, fasting plasma glucose level, postprandial plasma glucose level, insulin level, insulin resistance, blood lipid changes, and liver, kidney, and thyroid function indices were measured. After 6weeks, changes in fasting blood glucose, low-density lipoprotein cholesterol (LDL-C),and total cholesterol (TC) levels showed thatANKASCIN568 plus had amore favorable effect than the placebo. Compared to baseline, a statistically significant decrease of 8.5%, 10.3%, and 7.5% was observed in fasting blood glucose, LDL-C and, TC levels, respectively (p < 0.05 for all pairs). Therefore, ANKASCIN568 plus produced by Monascus purpureus NTU 568 fermentation may be a potentially useful agent for the regulation of blood glucose and blood lipids and for treatment of coronary artery diseases. Taiwan Food and Drug Administration 2016-07-30 /pmc/articles/PMC9332536/ /pubmed/28911684 http://dx.doi.org/10.1016/j.jfda.2016.06.011 Text en © 2017 Taiwan Food and Drug Administration https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC-BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ).
spellingShingle Original Article
Wang, Yin-Ruei
Liu, Sheng-Fu
Shen, You-Cheng
Chen, Chien-Li
Huang, Chine-Ning
Pan, Tzu-Ming
Wang, Chin-Kun
A randomized, double-blind clinical study to determine the effect of ANKASCIN 568 plus on blood glucose regulation
title A randomized, double-blind clinical study to determine the effect of ANKASCIN 568 plus on blood glucose regulation
title_full A randomized, double-blind clinical study to determine the effect of ANKASCIN 568 plus on blood glucose regulation
title_fullStr A randomized, double-blind clinical study to determine the effect of ANKASCIN 568 plus on blood glucose regulation
title_full_unstemmed A randomized, double-blind clinical study to determine the effect of ANKASCIN 568 plus on blood glucose regulation
title_short A randomized, double-blind clinical study to determine the effect of ANKASCIN 568 plus on blood glucose regulation
title_sort randomized, double-blind clinical study to determine the effect of ankascin 568 plus on blood glucose regulation
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9332536/
https://www.ncbi.nlm.nih.gov/pubmed/28911684
http://dx.doi.org/10.1016/j.jfda.2016.06.011
work_keys_str_mv AT wangyinruei arandomizeddoubleblindclinicalstudytodeterminetheeffectofankascin568plusonbloodglucoseregulation
AT liushengfu arandomizeddoubleblindclinicalstudytodeterminetheeffectofankascin568plusonbloodglucoseregulation
AT shenyoucheng arandomizeddoubleblindclinicalstudytodeterminetheeffectofankascin568plusonbloodglucoseregulation
AT chenchienli arandomizeddoubleblindclinicalstudytodeterminetheeffectofankascin568plusonbloodglucoseregulation
AT huangchinening arandomizeddoubleblindclinicalstudytodeterminetheeffectofankascin568plusonbloodglucoseregulation
AT pantzuming arandomizeddoubleblindclinicalstudytodeterminetheeffectofankascin568plusonbloodglucoseregulation
AT wangchinkun arandomizeddoubleblindclinicalstudytodeterminetheeffectofankascin568plusonbloodglucoseregulation
AT wangyinruei randomizeddoubleblindclinicalstudytodeterminetheeffectofankascin568plusonbloodglucoseregulation
AT liushengfu randomizeddoubleblindclinicalstudytodeterminetheeffectofankascin568plusonbloodglucoseregulation
AT shenyoucheng randomizeddoubleblindclinicalstudytodeterminetheeffectofankascin568plusonbloodglucoseregulation
AT chenchienli randomizeddoubleblindclinicalstudytodeterminetheeffectofankascin568plusonbloodglucoseregulation
AT huangchinening randomizeddoubleblindclinicalstudytodeterminetheeffectofankascin568plusonbloodglucoseregulation
AT pantzuming randomizeddoubleblindclinicalstudytodeterminetheeffectofankascin568plusonbloodglucoseregulation
AT wangchinkun randomizeddoubleblindclinicalstudytodeterminetheeffectofankascin568plusonbloodglucoseregulation